文献速递骨肿瘤关节外科

原发与翻修骨水泥型股骨远端假体在肉瘤保肢患者中的长期生存率如何

What Is the Long-term Survivorship of Primary and Revision Cemented Distal Femoral Replacements for Limb Salvage of Patients With Sarcoma?
PubMed 文献 · Clin Orthop Relat Res · 2022-08-08

该回顾性比较研究基于1980年至2018年806个骨水泥型假体数据库,分析309个骨水泥型股骨远端假体,其中原发218个、翻修91个,最终纳入原发205个和翻修62个进行分析。翻修假体全因翻修平均生存时间10年(95%CI 7至12)短于原发假体18年(95%CI 15至20),p<0.001。翻修假体再次翻修最常见原因为假体周围或假体骨折37%(23/62)和无菌性松动15%(9/62);控制切除长度、柄长、假体制造方式和多孔领存在后,柄直径小于15mm与骨水泥翻修股骨远端假体再次全因翻修相关(OR 4,95%CI 1至17,p=0.03)。

要点

  • 翻修骨水泥型股骨远端假体全因翻修平均生存时间10年(95%CI 7至12),短于原发假体的18年(95%CI 15至20)(p<0.001)。
  • 翻修假体再次翻修最常见原因为假体周围或假体骨折37%(23/62)和无菌性松动15%(9/62)。
  • 柄直径小于15mm与骨水泥翻修股骨远端假体再次全因翻修相关(OR 4,95%CI 1至17,p=0.03)。

核心结论

  • 作者认为,使用尽可能大直径的柄、或至少较原发假体增大柄直径,对骨水泥翻修股骨远端假体生存重要,也是其翻修实践的重要部分。
  • 作者认为,通过抗扭转设计(如定制横钉制造)提高翻修假体抗无菌性松动能力,可能是改善生存率的方法之一。
  • 作者认为,改进抗疲劳骨折的假体冶金学是另一方法。
  • 作者提出,下一步可能包括了解在解剖限制无法置入直径15mm或以上骨水泥柄的患者中,股骨骨干宽度与假体直径的最佳比值。

研究设计与样本

  • 回顾性比较研究,使用本机构自1980年开始纵向维护的806个骨水泥型假体数据库,评估截至2018年12月31日。
  • 365个股骨远端假体中,排除非原发骨肿瘤51个(14%)和无骨水泥重建5个(1%),余309个骨水泥型股骨远端假体。
  • 309个中,原发假体218个(71%),翻修假体91个(29%,均为翻修既往股骨远端假体)。
  • 原发假体分析组205个(排除13个随访不足2年者),翻修分析组62个(排除29个第二次或以上翻修者,仅纳入原发股骨远端假体翻修术后第一次翻修)。
  • 原发组男性57%(117/205),翻修组男性71%(44/62);骨肉瘤分别为75%(153/205)和73%(45/62);原发组平均年龄26±16岁,翻修组31±13岁(p=0.02);随访分别为136±122个月和141±101个月。

主要发现

  • 翻修股骨远端假体组全因翻修平均生存时间10年(95%CI 7至12),短于原发组的18年(95%CI 15至20)(p<0.001)。
  • 翻修假体需再次翻修的最常见并发症为假体周围或假体骨折37%(23/62)和无菌性松动15%(9/62)。
  • 原发假体并发症类型与翻修假体后续全因翻修风险无关。
  • 控制切除长度、柄长、假体制造方式(定制或模块化)和多孔领存在后,柄直径小于15mm与骨水泥翻修股骨远端假体再次全因翻修相关(OR 4,95%CI 1至17,p=0.03)。
  • 患者年龄、性别、放化疗史或原发肿瘤诊断等其他参数与再次翻修手术无关。

关键数值与推荐

  • 翻修股骨远端假体全因翻修平均生存时间10年(95%CI 7至12),原发假体18年(95%CI 15至20),p<0.001。
  • 翻修假体再次翻修原因:假体周围或假体骨折37%(23/62),无菌性松动15%(9/62)。
  • 柄直径小于15mm与骨水泥翻修股骨远端假体再次全因翻修相关:OR 4(95%CI 1至17),p=0.03。
  • 原发组平均年龄26±16岁,翻修组31±13岁(p=0.02)。
  • 原发组平均随访136±122个月,翻修组141±101个月。

临床怎么用

  • 作者认为,使用尽可能大直径的柄、或至少较原发假体增大柄直径,对骨水泥翻修股骨远端假体生存重要,也是其翻修实践的重要部分。
  • 作者认为,通过抗扭转设计(如定制横钉制造)提高翻修假体抗无菌性松动能力,可能是改善生存率的方法之一。
  • 作者认为,改进抗疲劳骨折的假体冶金学是另一方法。
  • 作者提出,下一步可能包括了解在解剖限制无法置入直径15mm或以上骨水泥柄的患者中,股骨骨干宽度与假体直径的最佳比值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cemented endoprosthetic reconstruction after resection of primary bone sarcomas has been in common use for decades. Although multiple studies have reported the survivorship of primary endoprostheses, implant survivorship after revision surgery is less well established. Given that earlier advances in systemic therapy improved survival of patients with sarcoma, the usage of revision endoprostheses can be expected to increase and, as such, understanding revision implant survivorship will help to inform patient and surgeon expectations. Additionally, as new implants are developed that allow alternative reconstruction options, a normative dataset establishing accurate expectations for revision cemented endoprostheses is a critical benchmark by which to measure progress. QUESTIONS/PURPOSES: (1) What is the implant survivorship free of all-cause revision for primary and revision cemented distal femoral replacements (DFRs) used in the treatment of malignant or benign tumors? (2) What are the most common indications for revision of primary and revision DFRs in an oncology population with mean follow-up of more than 10 years? (3) How does the indication for revision of a primary DFR affect the subsequent risk for and type of revision DFR complication? (4) What patient, tumor, or implant characteristics are associated with improved survivorship free of revision in cemented DFRs used in patients treated initially for primary malignant or benign tumors? METHODS: This was a retrospective, comparative study using our institution's longitudinally-maintained database of 806 cemented endoprostheses starting in 1980 and assessed through December 31, 2018. In all, 365 DFRs were inserted during this time, but 14% (51 of 365) were placed for nonprimary bone tumors and 1% (5 of 365) were cementless reconstructions, leaving 309 cemented DFRs. Seventy-one percent (218 of 309) were primary implants and 29 percent (91 of 309) were revision implants (used to revise a prior DFR in all patients). During this time period, our strong bias was to use cemented stems and, thus, nearly all of our patients had cemented stems. Six percent (13 of 218) of primary DFRs were implanted more than 2 years before the study end; however, they lacked 2 years of follow-up data and, thus, were considered lost to follow-up, leaving 205 implants in the primary DFR analysis group. Only the first revision after primary DFR revision surgery was included in the revision cohort analysis. Thirty-two percent (29 of 91) of revision DFRs were second or more revision patients and were excluded, leaving 62 implants in the revision analysis group. Most patients in both groups were men (57% [117 of 205] for primary and 71% [44 of 62] for revision) who had been diagnosed with osteosarcoma (75% [153 of 205] and 73% [45 of 62] for primary and revision, respectively). The primary cohort had mean age of 26 ± 16 years with a mean follow-up of 136 ± 122 months, and the revision cohort had mean age of 31 ± 13 years (p = 0.02) with 141 ± 101 months of follow-up. Study endpoints included all-cause implant revision and cause-specific revision for soft tissue complications, aseptic loosening, structural complications (defined as periprosthetic or implant fracture), infection, or tumor progression. Planned surgery for implant lengthening procedures was excluded. Implant survivorship free from all-cause revision was calculated using a competing risk (cumulative incidence) estimator with death as a competing risk. A log-rank test using chi-square analysis was used to evaluate the differences in implant survivorship between primary DFRs and first revisions. The cause-specific incidences of implant revision were tabulated for primary and revision DFRs. Cox regression analysis investigated the odds of subsequent all-cause revision surgery for revision cemented DFRs based on the primary implant complication. A binary logistic regression analysis using age, gender, indication for revision, tumor type, infection, perioperative chemotherapy, and radiation was performed to identify factors associated with a second DFR reoperation. Relative effect sizes are reported as ORs. RESULTS: The revision DFR cohort had a shorter mean survival to all-cause revision than the primary cohort (mean 10 years [95% CI 7 to 12] versus 18 years [95% CI 15 to 20]; p < 0.001). The most common complications necessitating revision for revision implants were periprosthetic or implant fracture in 37% (23 of 62) and aseptic loosening in 15% (9 of 62), and the type of primary implant complication was not associated with risk of subsequent all-cause revision surgery for revision implants. Stem diameter less than 15 mm was associated with repeat all-cause revision in cemented revision DFRs after controlling for resection length, stem length, implant fabrication (custom or modular), and presence of a porous collar (OR 4 [95% CI 1 to 17]; p = 0.03). No other parameters that we explored, including patient age, gender, chemoradiation history, or primary tumor diagnosis, were associated with repeat revision surgery. CONCLUSION: Understanding modifiable factors that can improve revision DFR survival is critical to achieving long-term limb salvage for patients with tumors around the knee. Our data suggest that utilizing implants with the largest possible stems-or at a minimum increasing the stem size over the primary implant-is important to revision cemented DFR survivorship and is an important part of our revision practice. Improving revision implants' resistance to aseptic loosening through designs that resist torsion (a common mode of cemented fixation failure)-such as with the use of custom cross-pin fabrication-may be one method to improve survivorship. Another will be improved implant metallurgy that is resistant to fatigue fracture. Next steps may include understanding the optimal ratio of femoral diaphyseal width to implant diameter in patients where anatomic constraints preclude the insertion of cemented stems 15 mm or more in diameter. LEVEL OF EVIDENCE: Level IV, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Geiger EJ, Arnold MT, Hart CM, et al. What Is the Long-term Survivorship of Primary and Revision Cemented Distal Femoral Replacements for Limb Salvage of Patients With Sarcoma? Clin Orthop Relat Res. 2022. PMID: 35943730. doi:10.1097/CORR.0000000000002333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。